使SSTR2.

Majid Momeny1, Solmaz AghaAmiri1, Servando Hernandez Vargas1

  • 1The Brown Foundation Institute of Molecular Medicine, McGovern Medical School, The University of Texas Health Science Center, Houston, TX 77054, USA.

Cancers
|January 25, 2025
PubMed
概括

针对体静止素受体2 (SSTR2) 的治疗药物对肝细胞癌 (HCC) 有前途. 这项研究证实了SSTR2在HCC中的表达,并证明了放射性标记类型的诊断和治疗潜力,用于检测和治疗这种癌症.